Benavente MA, Bianchi CP, Aba MA. Expression of
Arginine Vasopressin Type 2 Receptor in Canine Mammary Tumours: Preliminary Results.
J Comp Pathol 2020;
179:36-40. [PMID:
32958145 DOI:
10.1016/j.jcpa.2020.07.005]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Revised: 06/12/2020] [Accepted: 07/14/2020] [Indexed: 11/17/2022]
Abstract
The aims of this study were to investigate the potential association of arginine vasopressin type 2 receptor (AVPR2) in canine mammary tumours with expression of oestrogen receptors α (ORα) and β (ORβ) and clinicopathological features of the neoplasms. Twenty-six canine mammary tumour samples (11 benign, 15 malignant) were immunolabelled for AVPR2, ORα and ORβ antigens. Moderate to intense immunolabelling of AVPR2 antigen, found in all neoplasms, was not significantly associated with expression of ORα or ORβ antigens or with clinicopathological features. These findings indicate a potential role for AVPR2 in the development of canine mammary tumours and the use of AVPR2-selective vasopressin analogues as therapeutic options.
Collapse